Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study
Early treatment, lower T stage, the absence of ascites, and lower pre-IBIL, post-CA125, CA199, CA724, and PLR correlate with better OS. Factors for improved PFS include early treatment, lower T stage, fewer metastatic sites, and lower pre-IBIL, post-GLOB, and post-CA125 levels. Nomogram models can help identify patients who may benefit from immunotherapy, providing valuable clinical guidance.
Authors
- Lulu Guan
- Feng Wang (ORCID: https://orcid.org/0000-0001-7668-9674)
- Bingtong Yue (ORCID: https://orcid.org/0009-0000-6458-0612)
- Dao Xin (ORCID: https://orcid.org/0000-0002-6172-7727)
- Qifan Zhang (ORCID: https://orcid.org/0000-0002-1272-3156)
- Yuanyuan Yang (ORCID: https://orcid.org/0000-0002-7041-0115)
- Zhe Wang (ORCID: https://orcid.org/0000-0003-0786-9887)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Zhengzhou University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Henan Provincial Center for Disease Control and Prevention (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.3389/fimmu.2024.1468342
- Citations
- 6
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.51